Close

Cortexyme (CRTX) Announces Clinical Hold on Atuzaginstat's Investigational New Drug Application

Go back to Cortexyme (CRTX) Announces Clinical Hold on Atuzaginstat's Investigational New Drug Application

Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application

January 26, 2022 8:00 AM EST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimers and other degenerative diseases, today announced that the company received a letter from the U.S. Food and Drug Administration (FDA) on January 25, 2022 placing a full clinical hold on atuzaginstats (COR388) Investigational New Drug application (IND 134303). The company plans to provide additional updates pending continued engagement with FDA.

Cortexyme is immediately implementing a cost reduction program to rationalize operations and to allow continued support for planned clinical milestones, providing an expected cash runway... More